Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism

 
• By Joseph Haas
  
Bristol-Myers-Squib_685347493_1200.jpg
Bristol sees positive early trends for the Opdivo/Yervoy combo in first-line lung cancer
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business